Novo Nordisk (NYSE:NVO) announced a strategic shift in its commercial approach on Tuesday, March 31, 2026, launching a multi-month subscription program for its flagship obesity medication, Wegovy.
The initiative aims to lower the financial barrier for self-pay patients while addressing the persistent industry challenge of long-term treatment adherence.
The program offers eligible patients the choice of three, six, or 12-month plans, with the deepest discounts reserved for year-long commitments.
Under a 12-month subscription, both the Wegovy injection and the recently approved pill version are priced at $249 per month.
For injection users, this represents an annual savings of $1,200 compared to standard monthly pricing, while pill users save approximately $600 per year.
A key feature of the plan is price stability; monthly costs remain flat even if a patient’s dosage increases during the subscription period.
The rollout is being executed through prominent telehealth partnerships, including Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame expected to join the platform shortly.
Notably, the program is not yet available through Novo Nordisk’s proprietary NovoCare direct-to-consumer pharmacy.
The launch comes at a critical juncture for Novo Nordisk, which currently holds roughly 39% of the branded U.S. GLP-1 market, trailing Eli Lilly’s 60% share.
While Novo’s oral Wegovy saw strong early uptake following its late 2025 approval, Eli Lilly is expected to introduce a competing oral GLP-1 later this year.
By locking patients into multi-month plans, Novo Nordisk aims to mitigate the high attrition rates seen in the category; 2025 data indicated that 65% of obesity patients discontinue treatment within a single year.
Financially, the subscription model arrives as Novo Nordisk guides for declining sales and profit in 2026, driven by intense pricing pressures and the rising cost of market share acquisition.